Backgroundand study aims:Hepatitis C virus (HCV) is the main leading cause of liver disease in Egypt. A new era of HCV treatment has been started with the evolution of direct acting antiviral agents. Sofosbuvir (SOF)-based therapy was introduced by the Egyptian ministry of health in 2014 in an attempt to decrease disease burden. We aimed to evaluate efficacy and safety of Sofosbuvir-based regimens in HCV Egyptian patients with compensated liver disease.
Patients andMethod:This study was conducted in National Liver Institute, MenoufiaUniversity, Egypt. Seven hundred patients out of seven hundred fifty-eight chronic HCV patients with compensated liver disease who met the inclusion criteria were included. According to treatment regimen patients were divided to 4 groups; group 1 received Sofosbuvir (SOF), Pegylated interferon (PEG-IFN) plus ribavirin (RBV), group 2 received SOF plus RBV, group 3 received SOF and Simeprevir± RBV, group 4 received SOF and Daclatasvir ±RBV. Results:The overall SVR was 90.9%, 81.5%, 95% and 98% in groups 1, 2, 3, and 4 respectively. SVR in patients with liver cirrhosis was 90.56, 79.16, 95 and 96% in the 4 groups respectively. In treatment experienced patients, SVR was 86.8% in group 1, 78.3% in group 2, 100% in group 3 and 86.7% in group 4. Conclusion: Sofosbuvir plus daclatasvir with or without ribavirin is the safest andmost effective SOF-based regimen in treatment of HCV Egyptian patients with compensated liver disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.